Eidos Therapeutics (NASDAQ:EIDX) Trading 9.1% Higher

Shares of Eidos Therapeutics Inc (NASDAQ:EIDX) traded up 9.1% on Wednesday . The stock traded as high as $65.71 and last traded at $65.60, 165,533 shares changed hands during trading. An increase of 2% from the average session volume of 161,664 shares. The stock had previously closed at $60.15.

Several research analysts have weighed in on the stock. BTIG Research set a $56.00 price objective on shares of Eidos Therapeutics and gave the stock a “buy” rating in a report on Tuesday, October 15th. Roth Capital raised their price objective on shares of Eidos Therapeutics from $51.00 to $57.00 and gave the stock a “buy” rating in a report on Friday, November 1st. Barclays lowered shares of Eidos Therapeutics from an “overweight” rating to an “equal weight” rating and raised their price objective for the stock from $37.00 to $45.00 in a report on Friday, November 1st. Zacks Investment Research raised shares of Eidos Therapeutics from a “hold” rating to a “buy” rating and set a $52.00 price objective for the company in a report on Monday, November 18th. Finally, ValuEngine lowered shares of Eidos Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, October 2nd. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $52.00.

The company’s fifty day moving average price is $51.55 and its 200 day moving average price is $40.31. The company has a debt-to-equity ratio of 0.03, a quick ratio of 17.00 and a current ratio of 17.00. The firm has a market capitalization of $2.46 billion, a price-to-earnings ratio of -34.14 and a beta of -0.86.

Eidos Therapeutics (NASDAQ:EIDX) last posted its quarterly earnings results on Thursday, October 31st. The company reported $0.18 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.30) by $0.48. The business had revenue of $26.69 million during the quarter. As a group, sell-side analysts expect that Eidos Therapeutics Inc will post -1.07 earnings per share for the current year.

In other news, CFO Christine Siu sold 20,000 shares of Eidos Therapeutics stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $59.75, for a total value of $1,195,000.00. Also, insider Jonathan C. Fox sold 5,000 shares of Eidos Therapeutics stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $45.74, for a total transaction of $228,700.00. Insiders sold a total of 112,500 shares of company stock valued at $6,273,275 over the last ninety days. Company insiders own 70.10% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of Montreal Can boosted its holdings in shares of Eidos Therapeutics by 151.8% in the 2nd quarter. Bank of Montreal Can now owns 1,385 shares of the company’s stock valued at $43,000 after buying an additional 835 shares during the period. SG Americas Securities LLC acquired a new position in shares of Eidos Therapeutics in the 2nd quarter valued at about $125,000. Metropolitan Life Insurance Co NY acquired a new position in shares of Eidos Therapeutics in the 1st quarter valued at about $143,000. Strs Ohio boosted its stake in Eidos Therapeutics by 457.1% during the 2nd quarter. Strs Ohio now owns 11,700 shares of the company’s stock valued at $363,000 after purchasing an additional 9,600 shares during the period. Finally, Swiss National Bank acquired a new position in Eidos Therapeutics during the 2nd quarter valued at about $426,000. 30.46% of the stock is owned by institutional investors and hedge funds.

About Eidos Therapeutics (NASDAQ:EIDX)

Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.

Read More: Why Invest in High-Yield Dividend Stocks?

Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.